^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pumitamig (BNT327)

    i
    Other names: BNT327, BMS986545, PM8002, PM 8002, PM-8002, BNT 327, BNT-327, BMS-986545
    Company:
    BioNTech, BMS
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    1m
    BNT314-02: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=482, Recruiting, BioNTech SE | Trial completion date: May 2031 --> Dec 2032
    Trial completion date
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • pumitamig (BNT327)
    2ms
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=594, Recruiting, BioNTech SE | Trial completion date: Jun 2031 --> May 2032 | Trial primary completion date: Aug 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    pumitamig (BNT327) • BNT324
    2ms
    BNT323-03: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=380, Recruiting, BioNTech SE | Trial completion date: May 2029 --> Aug 2029 | Trial primary completion date: May 2028 --> Aug 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab pamirtecan (BNT323) • pumitamig (BNT327)
    2ms
    DB-1311-201: DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (2025-523895-22-00)
    P1/2, N=102, Not yet recruiting, Dualitybio Inc. | N=57 --> 102
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    2ms
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=31, Completed, Biotheus Inc. | Recruiting --> Completed | N=55 --> 31 | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • pemetrexed • pumitamig (BNT327)
    2ms
    CA052-002: A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=1109, Recruiting, Bristol-Myers Squibb | Trial completion date: Jul 2028 --> Aug 2031 | Trial primary completion date: Jul 2028 --> Aug 2031
    Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • docetaxel • pumitamig (BNT327)
    2ms
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=198, Recruiting, Bristol-Myers Squibb | N=129 --> 198
    Enrollment change
    |
    Yervoy (ipilimumab) • pumitamig (BNT327)
    3ms
    CA2660001: A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC (2025-523576-23-00)
    P2/3, N=62, Not yet recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • pumitamig (BNT327)
    3ms
    PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, Biotheus Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    paclitaxel • topotecan • pumitamig (BNT327)
    3ms
    CA2660002: A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ? 50% (2025-523586-18-00)
    P2/3, N=15, Not yet recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • pumitamig (BNT327)
    3ms
    DB-1311-201: DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (2025-523895-22-00)
    P1/2, N=57, Not yet recruiting, Dualitybio Inc.
    New P1/2 trial
    |
    pumitamig (BNT327) • BNT324
    3ms
    Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MTAP (Methylthioadenosine Phosphorylase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    navlimetostat (BMS-986504) • pumitamig (BNT327)